telitacicept in individuals with IgA nephropathy (IgAN). The research aimed to provide practical evidence regarding the clinical benefits of this dual B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) inhibitor in managing IgAN.
The retrospective, single-center study included 33 patients diagnosed with IgA nephropathy. Among them, 11 patients received telitacicept for at least three months, while a control group was established through propensity score matching to ensure comparability. Clinical and laboratory assessments were performed at baseline and then every 1 to 3 months during the 6-month follow-up period.
The investigators acknowledged several limitations, including the small sample size, relatively short follow-up duration, and incomplete post-treatment data for immunological markers such as IgA and Gd-IgA. Additionally, potential racial differences and variations in treatment regimens may have influenced the results. The researchers emphasized the need for large-scale, multicenter randomized controlled trials with longer follow-up and standardized treatment protocols to confirm these findings and evaluate the cost-effectiveness of telitacicept.
"The study supports the therapeutic potential of telitacicept as an effective and safe treatment option for patients with IgA nephropathy. While preliminary, these findings highlight telitacicept’s promise as an alternative approach for reducing proteinuria and preserving kidney function in IgAN management," the authors concluded.
Li, H., Zhang, Y. & Zhang, C. Effectiveness and safety of telitacicept in IgA nephropathy: a propensity score matching analysis with a 6-month follow-up. BMC Nephrol 26, 546 (2025). https://doi.org/10.1186/s12882-025-04468-7
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.